Phase II study of goserelin adjuvant therapy combined with exemestane with or without tibolone in premenopausal women with receptor positive, node negative mammary carcinoma: ADAGIO study;Phase-II-studie zur kombinierten exemestan- und goserelin-adjuvanz-therapie mit und ohne tibolon bei prämenopausalen frauen mit rezeptorpositivem und nodal-negativem mammakarzinom: ADAGIO-studie

Geburtshilfe und Frauenheilkunde

Volumn 65, Issue 6, 2005, Pages 612-619

  Pollow, Kunhard ^a   Schaffrath, M ^a   Kolb H ^a   Lebrecht, A ^a   Schonegg W ^b   Hoffmann, C ^c   Elling, D ^d   Kohler U ^e   Winzer, K ^f   Kreienberg, R ^g   Du Bois, A ^h  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Niedergelassener Gynäkologe   (Germany)

^c Frauenklinik   (Germany)

^d Oskar Ziethen Hospital   (Germany)

^e Klinikum St Georg   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FOLLITROPIN; GOSERELIN; LUTEINIZING HORMONE; TIBOLONE;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; FEMALE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; LIBIDO DISORDER; MENOPAUSAL SYNDROME; MULTICENTER STUDY; OSTEOLYSIS; OVARY FUNCTION; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VAGINA DISEASE;

EID: 21444461123     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-865726     Document Type: Article

References (34)

1. Diesing D, Diedrich K, Friedrich M. Chemoendokrine Therapie des Mammakarzinoms bei prämenopausalen Patientinnen. Geburtsh Frauenheilk 2004; 64: 793-799
2. Robertson JF, Blarney RW. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. Eur J Cancer 2003; 39: 861-869
3. Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Current status of endocrine therapy for breast cancer. Breast Cancer 2003; 10: 105-111
4. Baum M, O'Shaughnessy JA. Management of premenopausal women with early-stage breast cancer: is there a role for ovarian suppression? Clin Breast Cancer 2002; 3: 260-267
5. Lonning PE. Exemestane: a review of its clinical efficacy and safety. Breast 2001; 10: 198-208
6. de Gooyer ME, Deckers GH, Schoonen WGEJ, Verheul HAM, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003; 68: 21-30
7. Kloosterboer HJ, Ederveen AGH. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (progestogen) treatments. J Steroid Biochem Mol Biol 2003; 83: 157-165
8. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. (The Menopause Rating Scale [MRSII]: methodological standardization in the German population). Zentralbl Gynäkol 2000; 122: 280-286
9. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ.-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376
10. Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol 2002; 12 (Suppl 1): 1-3
11. Johannessen DC, Engan T, Salle ED, Zurlo G, Paolini J, Omati G, Piscitelli G, Kvinsland S, Lonning E. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients: a phase I study. Clin Cancer Research 1997; 3: 1101-1108
12. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999; 106 (Suppl 19): 1-21
13. Taskin O, Yalcinoglu Al, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 1997; 67: 40-45
14. Lindsay PC, Shaw RW, Coelingh Bennink HJ, Kovic P. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotrophin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996; 65: 342-348
15. Uryan II, Taskin O, Erden F, Buhur A, Burak A, Burak F, Ozekici U, Wheeler JM. Effectiveness and long-term safety of prolonged goserelin and tibolone in women with endometriosis. J Am Assoc Gynecol Laparosc 1996; 3 (Suppl 4): 51-52
16. Palomba S, Affinito P, Tommaselli GA, Nappi C. A clinical trial of the effects of tibolone administered with gonadotrophin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998; 70: 111-118
17. Gregoriou O, Vitaratos N, Papadias C, Konidaris S, Constomenos D, Chryssikopoulas A. Effect of tibolone on postmenopausal women with myomas. Maturitas 1997; 27: 187-191
18. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long-term administration of tibolone plus gonadotrophin-releasing hormone agonist for the treatment of uterine leiomyomas: effectiveness and effects on vasomotor Symptoms, bone mass and lipid profile. Fertil Steril 1999; 72: 889-895
19. Kroiss R, Fentiman IS, Heimond F, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG 2005; 112: 228-233
20. Kloosterboer HJ. New mechanisms of action for tibolone in breast cancer. In: Neves-e-Castro M, Wren BG (eds). Menopause Hormones and Cancer. New York: Parthenon, 2003: 37-47
21. Gompel A, Chaouat M, Jacob D, Perrot J-Y, Kloosterboer HJ, Rostene W. In vitro studies of tibolone in breast cells. Fertil Steril 2002; 78: 351-359
22. Gompel A, Kandouz M, Siromachkova M. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecol Endocrinol 1997; 11 (Suppl 1): 77-79
23. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994; 49: 311-318
24. Kloosterboer HJ, Deckers GH. Effects of tibolone (Livial®) and its metabolites on the growth of DMBA induced tumors in rats. Acta Obstet Gynaecol Scand 1997; 76 (Suppl 167): 59
25. Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004; 109: 721-727
26. Holmberg L, Anderson A. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison: trial stopped. Lancet 2004, 363: 453-455
27. Jantke A, Buhling KJ, Sehouli J, Pfüller B, Hindenburg H-J, Lichtenegger W. Zum Einfluss der WHI-Studie auf die Hormonsubstitution in der Praxis - Ergebnisse einer Umfrage unter Frauenärzten/innen in Berlin. Geburtsh Frauenheilk 2003; 63: 560-565
28. Velthuis-te Wierik EJM, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen + progestogen therapies: a UK MediPlus study. Climacteric 2004; 7: 97-209
29. Olsson HJ. Brest tolerance, tibolone compared with other hormonal treatments. EJC 2004; 2 (Suppl): 79-80
30. Klosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas 2004; 49: 5-15
31. Lundstrom E, Christow A, Kersenmaekers W. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186: 717-722
32. Valdivia I, Campodonico I, Tapia A, Capetilla M, Espinoza A, Lavin P. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004; 81: 617-623
33. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904-911
34. Huber J, Palacios S, Berglund L, Hänggi W, Sathanandan SM, Christau S, Helmond F. Effects of tibolon and continuous combined hormone replacement therapie on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 202; 109: 886-893